Compared with patients with ER-PR-HER2+ breast cancer, those with TPBC or ER+PR-HER2+ breast cancer had significantly better BCSS and OS (all log-rank P < 0.001) (Figure 1). This evidence concerns the gene ESR1 and breast carcinoma.